Table 1 Demographics and characteristics of the PSC, UC, and HC subjects used.
PSC | UC | HC | p-value | |
|---|---|---|---|---|
Number of patients | 24 | 16 | 24 | |
Male, n (%) | 16 (67) | 7 (44) | 10 (42) | 0.172 |
Present age, yrs, median (IQR) | 12.5 (9.5–17.5) | 12.5 (11.5–15.5) | 11.5 (5.5–16) | 0.467 |
Age at onset, yrs, median (IQR) | 6 (3–10) | 11 (7.5–12.5) | — | 0.026 |
Age at diagnosis, yrs, median (IQR) | 9 (6–12) | 12 (9–13) | — | 0.161 |
PSC phenotype n (%) | ||||
Large duct PSC | 23 (96) | — | — | |
Small duct PSC | 1 (4) | — | — | |
Overlap with autoimmune hepatitis | 14 (58) | — | — | |
Type of IBD, n (%) | 24 (100) | 16 (100) | — | 1.000 |
UC | 10 (42) | 16 (100) | — | <0.001 |
IBD-U | 14 (58) | 0 (0) | — | <0.001 |
PUCAI score in UC patients, n (%) | ||||
Remission (0–9) | 7 (70) | 8 (50) | — | 0.428 |
Mild (10–30) | 3 (30) | 5 (31) | — | 0.945 |
Moderate to severe (35–) | 0 (0) | 3 (19) | — | 0.262 |
Biochemical data, median (IQR) | ||||
Platelets, 109/μL | 274.5 (240.5–341.5) | 270.5 (240.5–366.0) | — | 0.801 |
Albumin, g/dL | 4.45 (4.1–4.75) | 4.5 (3.85–4.6) | — | 0.617 |
AST, IU/L | 55 (24.5–84) | 22 (19.5–24) | — | <0.001 |
ALT, IU/L | 42.5 (15.5–98.5) | 13.5 (12–20.5) | — | 0.003 |
GGT, IU/L | 60.5 (12.5–131) | 12 (10–17) | — | <0.001 |
APRI | 0.42 (0.22–1.25) | 0.22 (0.17–0.25) | — | 0.002 |
Medication n (%) | ||||
UDCA | 20(83) | 0 (0) | — | <0.001 |
SASP | 13 (54) | 1 (6) | — | 0.002 |
Mesalazine | 5 (21) | 14 (88) | — | <0.001 |
Immunosuppresive | 9 (38) | 10 (63) | — | 0.220 |
Steroids | 6 (25) | 2 (13) | — | 0.439 |
Probiotics | 5 (21) | 6 (38) | — | 0.277 |
